A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial
Date
2019Author
Kocer, Belgin
Saip, Sabahattin
Tuncer, Asli
Kasap, Mithat
Caliskan, Zeynep
Akman Demir, Gulsen
Turkoglu, Recai
Yuceyar, Nur
EFENDİ, HÜSNÜ
TURAN, ÖMER FARUK
AĞAN YILDIRIM, KADRİYE
TERZİ, MURAT
BOZ, CAVİT
Metadata
Show full item recordAbstract
Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.
Collections
- Makale [92796]